Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05HDX
|
|||
| Former ID |
DNC004589
|
|||
| Drug Name |
GW-501516
|
|||
| Synonyms |
317318-70-0; GW501516; GW 501516; Endurobol; GW-501516; GSK-516; UNII-7I2HA1NU22; GW1516; GW 1516; 2-(2-Methyl-4-(((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methyl)thio)phenoxy)acetic acid; GW-516; GW-1516; CHEMBL38943; 2-(2-methyl-4-((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methylthio)phenoxy)acetic acid; 2-(4-((2-(4-(Trifluoromethyl)phenyl)-4-methylthiazol-5-yl)methylthio)-2-methylphenoxy)acetic acid; 7I2HA1NU22
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Type-1 diabetes [ICD-11: 5A10; ICD-9: 250] | Discontinued in Phase 4 | [1], [2] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H18F3NO3S2
|
|||
| Canonical SMILES |
CC1=C(C=CC(=C1)SCC2=C(N=C(S2)C3=CC=C(C=C3)C(F)(F)F)C)OCC(=O)O
|
|||
| InChI |
1S/C21H18F3NO3S2/c1-12-9-16(7-8-17(12)28-10-19(26)27)29-11-18-13(2)25-20(30-18)14-3-5-15(6-4-14)21(22,23)24/h3-9H,10-11H2,1-2H3,(H,26,27)
|
|||
| InChIKey |
YDBLKRPLXZNVNB-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 317318-70-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
14760044, 22395218, 24112236, 44839960, 47805477, 48179654, 50076238, 56312057, 56314038, 57373382, 58097849, 76715573, 80155172, 85247949, 93307716, 99460836, 103215364, 123051099, 126625906, 126652900, 126680734, 134341794, 135262703, 135650336, 135693136, 137001050, 137082307, 137275846, 140051368, 143497106, 152104522, 152238470, 152258269, 160647106, 160812273, 162123186, 162263950, 163375554, 163425821, 164194070, 164842066, 165835041, 175426999, 177749053, 185964690, 187071867, 196107111, 198963667, 204419906, 223395970
|
|||
| ChEBI ID |
CHEBI:73726
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Peroxisome proliferator-activated receptor delta (PPARD) | Target Info | Modulator | [3] |
| KEGG Pathway | PPAR signaling pathway | |||
| Wnt signaling pathway | ||||
| Pathways in cancer | ||||
| Acute myeloid leukemia | ||||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Panther Pathway | Wnt signaling pathway | |||
| Pathway Interaction Database | Presenilin action in Notch and Wnt signaling | |||
| RXR and RAR heterodimerization with other nuclear receptor | ||||
| Reactome | Import of palmitoyl-CoA into the mitochondrial matrix | |||
| Regulation of pyruvate dehydrogenase (PDH) complex | ||||
| Nuclear Receptor transcription pathway | ||||
| WikiPathways | Wnt Signaling Pathway and Pluripotency | |||
| Nuclear Receptors in Lipid Metabolism and Toxicity | ||||
| NRF2 pathway | ||||
| Nuclear Receptors Meta-Pathway | ||||
| Vitamin D Receptor Pathway | ||||
| Ectoderm Differentiation | ||||
| Adipogenesis | ||||
| Nuclear Receptors | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2687). | |||
| REF 2 | ClinicalTrials.gov (NCT00841217) Regulation of Lipoprotein Transport in Metabolic Syndrome. U.S. National Institutes of Health. | |||
| REF 3 | Lipid effects of peroxisome proliferator-activated receptor- agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome.Arterioscler Thromb Vasc Biol.2012 Sep;32(9):2289-94. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.